These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10227715)

  • 1. Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage.
    Fleishaker JC; Fiedler-Kelly J; Grasela TH
    Pharm Res; 1999 Apr; 16(4):575-83. PubMed ID: 10227715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of tirilazad clearance by phenytoin.
    Fleishaker JC; Pearson LK; Peters GR
    Biopharm Drug Dispos; 1998 Mar; 19(2):91-6. PubMed ID: 9533108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital.
    Fleishaker JC; Pearson LK; Peters GR
    Eur J Clin Pharmacol; 1996; 50(1-2):139-45. PubMed ID: 8739825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    Clin Pharmacol Ther; 1994 Oct; 56(4):389-97. PubMed ID: 7955800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis.
    Pearson LK; Fleishaker JC; Peters GR
    Eur J Clin Pharmacol; 1996; 50(4):299-304. PubMed ID: 8803523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age and gender on tirilazad pharmacokinetics in humans.
    Hulst LK; Fleishaker JC; Peters GR; Harry JD; Wright DM; Ward P
    Clin Pharmacol Ther; 1994 Apr; 55(4):378-84. PubMed ID: 8162663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day.
    Fleishaker JC; Peters GR
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):28-32. PubMed ID: 9021439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
    Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM
    J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults.
    Fleishaker JC; Straw RN; Cross CJ
    J Pharm Sci; 1997 Apr; 86(4):434-7. PubMed ID: 9109044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    Int J Clin Pharmacol Ther; 1994 May; 32(5):223-30. PubMed ID: 7921515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A.
    Fleishaker JC; Pearson LK; Pearson PG; Wienkers LC; Hopkins NK; Peters GR
    J Clin Pharmacol; 1999 Mar; 39(3):260-7. PubMed ID: 10073325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury.
    Smith SL; Scherch HM; Hall ED
    J Neurosurg; 1996 Feb; 84(2):229-33. PubMed ID: 8592225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers.
    Fleishaker JC; Hulst LK; Peters GR
    J Clin Pharmacol; 1994 Aug; 34(8):837-41. PubMed ID: 7962672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study.
    Haley EC; Kassell NF; Alves WM; Weir BK; Hansen CA
    J Neurosurg; 1995 May; 82(5):786-90. PubMed ID: 7714603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa.
    Lanzino G; Kassell NF; Dorsch NW; Pasqualin A; Brandt L; Schmiedek P; Truskowski LL; Alves WM
    J Neurosurg; 1999 Jun; 90(6):1011-7. PubMed ID: 10350245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tirilazad mesylate on vasospasm and phospholipid hydroperoxides in a primate model of subarachnoid hemorrhage.
    Suzuki H; Kanamaru K; Kuroki M; Sun H; Waga S; Miyazawa T
    Stroke; 1999 Feb; 30(2):450-5; discussion 455-6. PubMed ID: 9933286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage.
    Kim DW; Kim TE; Ji M; Chun YI
    Clin Neuropharmacol; 2015; 38(6):248-51. PubMed ID: 26536021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirilazad for aneurysmal subarachnoid haemorrhage.
    Zhang S; Wang L; Liu M; Wu B
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006778. PubMed ID: 20166088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand.
    Kassell NF; Haley EC; Apperson-Hansen C; Alves WM
    J Neurosurg; 1996 Feb; 84(2):221-8. PubMed ID: 8592224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad.
    Fleishaker JC; Peters GR
    J Clin Pharmacol; 1996 Sep; 36(9):809-13. PubMed ID: 8889901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.